Syros Pharmaceuticals (0S90) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Sy-2101, Arsenic Trioxide | Acute Promyelocytic Leukemia | Phase I | Suspended | A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia | Aug 03, 2021 | ― |
| Venetoclax, Azacitidine, Tamibarotene | Acute Myeloid Leukemia | Phase II | Terminated | Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) | May 24, 2021 | ― |
| Azacitidine, Tamibarotene | Myelodysplastic Syndromes | Phase III | Terminated | Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome | Mar 11, 2021 | ― |
| Gemcitabine, Nab-paclitaxel, Fulvestrant, Sy-5609 | Small-cell Lung Cancer, Breast Cancer, Pancreatic Cancer, Advanced Solid Tumor | Phase I | Completed | A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors | Jan 22, 2020 | ― |
| Carboplatin, Fulvestrant, Sy-1365 (Part 1), Sy-1365 (Cohort 2), Sy-1365 (Cohort 5), Sy-1365 (Part 2 Single Agent) | Ovarian Cancer, Breast Cancer, Advanced Solid Tumors | Phase I | Terminated | A Study of SY-1365 in Adult Patients With Advanced Solid Tumors | Apr 19, 2017 | ― |
| Daratumumab, Azacitidine, Tamibarotene | Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase II | Completed | A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome | Jun 13, 2016 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Sy-2101, Arsenic Trioxide | Phase I | Acute Promyelocytic Leukemia | Suspended | A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia | Aug 03, 2021 | ― |
| Venetoclax, Azacitidine, Tamibarotene | Phase II | Acute Myeloid Leukemia | Terminated | Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) | May 24, 2021 | ― |
| Azacitidine, Tamibarotene | Phase III | Myelodysplastic Syndromes | Terminated | Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome | Mar 11, 2021 | ― |
| Gemcitabine, Nab-paclitaxel, Fulvestrant, Sy-5609 | Phase I | Small-cell Lung Cancer, Breast Cancer, Pancreatic Cancer, Advanced Solid Tumor | Completed | A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors | Jan 22, 2020 | ― |
| Carboplatin, Fulvestrant, Sy-1365 (Part 1), Sy-1365 (Cohort 2), Sy-1365 (Cohort 5), Sy-1365 (Part 2 Single Agent) | Phase I | Ovarian Cancer, Breast Cancer, Advanced Solid Tumors | Terminated | A Study of SY-1365 in Adult Patients With Advanced Solid Tumors | Apr 19, 2017 | ― |
| Daratumumab, Azacitidine, Tamibarotene | Phase II | Acute Myeloid Leukemia, Myelodysplastic Syndrome | Completed | A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome | Jun 13, 2016 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Syros Pharmaceuticals (DE:0S90) have in its pipeline
Syros Pharmaceuticals DE:0S90 is currently developing the following drugs: Sy-2101, Arsenic Trioxide, Venetoclax, Azacitidine, Tamibarotene, Azacitidine, Tamibarotene, Gemcitabine, Nab-paclitaxel, Fulvestrant, Sy-5609, Carboplatin, Fulvestrant, Sy-1365 (Part 1), Sy-1365 (Cohort 2), Sy-1365 (Cohort 5), Sy-1365 (Part 2 Single Agent), Daratumumab, Azacitidine, Tamibarotene. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
